Pulmosat’s design technology is based on a recently discovered property of our new Multiple Drug Resistant (MDR) antibacterial and antiviral “Psat” molecule to combat previously very difficult to treat lung diseases.
With our tremendously exciting clinical treatment possibilities, Pulmosat stands at the forefront of new drug development for difficult to treat lung pathology.